Evidence reviewed: 9 November 2026. Osteoarthritis (OA) and rheumatoid arthritis (RA) both cause joint pain and stiffness, but they have different underlying mechanisms, patterns of illness and treatment goals. OA is a whole-joint degenerative and remodeling disorder, often affecting knees, hips and hands. RA is a systemic autoimmune inflammatory disease that can damage joints and affect other organs if inadequately treated. This distinction matters because OA management centers on exercise, rehabilitation and symptom relief, whereas RA usually requires early disease-modifying antirheumatic drugs (DMARDs). The American College of Rheumatology (ACR) updated its OA guidance on 14 September 2026, and EULAR issued a 2025 RA treatment update published in March–June 2026 [1–4].
OA versus RA: clinical comparison
| Feature | Osteoarthritis (OA) | Rheumatoid arthritis (RA) |
|---|---|---|
| Main mechanism | Joint cartilage and subchondral bone remodeling with local inflammation. | Immune-mediated synovitis and systemic inflammatory pathways. |
| Common joints | Knees, hips, first carpometacarpal/thumb-base and finger DIP/PIP joints. | Often MCP and PIP joints of hands, wrists and MTP joints of feet. |
| Symmetry | May be asymmetric or associated with mechanical loading. | Often symmetric, but early RA need not be perfectly symmetric. |
| Stiffness | Usually brief morning stiffness, often under 30 minutes. | Often prolonged morning stiffness, commonly over 30–60 minutes. |
| Joint swelling | Bony enlargement and occasional effusion. | Soft, warm synovial swelling with tenderness. |
| Systemic symptoms | Usually limited; fatigue may follow poor sleep/pain. | Fatigue and sometimes low-grade fever or extra-articular disease. |
| Blood tests | No single diagnostic biomarker; ESR/CRP often normal. | RF, anti-CCP and inflammatory markers may support diagnosis but can be negative. |
| Primary treatment approach | Education, exercise, weight management when applicable, analgesia and selected procedures. | Early DMARDs, treat-to-target monitoring, rehabilitation and risk management. |
Patterns overlap. Some individuals have OA in several joints, RA may begin asymmetrically, and both can coexist. Neither a normal blood test nor an isolated finger-joint location can replace clinical evaluation [1–4].
What causes osteoarthritis?
OA involves altered mechanical and biological processes across articular cartilage, subchondral bone, synovium, ligaments and surrounding muscles. Risk factors include age, prior injury, repetitive loading, joint alignment, genetics and higher body weight for load-bearing joints. Low-grade inflammatory processes can contribute, so OA should not be described as merely passive “wear and tear” [1].
OA can cause crepitus, pain with use, reduced range of motion, bony enlargement and short-lived stiffness after rest. Symptoms do not always correlate closely with X-ray severity. Some patients with marked radiographic OA have limited pain, while others have major functional symptoms with modest imaging changes.
What causes rheumatoid arthritis?
RA involves chronic immune activation in the synovial lining, involving pathways such as TNF, IL-6 and adaptive autoimmunity. Proliferating inflammatory synovium can injure cartilage, tendons and bone, with erosions and deformity over time if inflammation remains uncontrolled [2,3].
Risk is associated with genetic predisposition, smoking and some environmental factors, but no single factor causes all RA. RA can affect the lungs, eyes, blood vessels and other tissues; it also increases cardiovascular risk. Early diagnosis and appropriate treatment reduce long-term joint damage.
Which joints are most commonly affected?
Hand OA frequently affects the distal interphalangeal (DIP) and proximal interphalangeal (PIP) joints and the thumb base, with bony nodules sometimes termed Heberden or Bouchard nodes. Knee OA often causes pain during walking or stairs, and hip OA may cause groin pain and limited internal rotation.
RA frequently involves metacarpophalangeal (MCP), PIP, wrist and forefoot joints, often with symmetrical inflammatory swelling. DIP involvement is less characteristic, but not sufficient to exclude RA. Joint patterns should be integrated with examination, history and targeted investigations.
Morning stiffness and inflammatory versus mechanical pain
In OA, stiffness often improves within a short period of movement and pain may increase with prolonged use. In RA, prolonged morning stiffness, warmth, persistent swelling and pain at rest can suggest active inflammation. However, stiffness duration is not a definitive diagnostic test, and inflammatory arthritis can mimic other joint diseases.
Sudden severe pain in one hot swollen joint, especially with fever, must be evaluated for septic arthritis and sometimes crystal arthritis (gout or pseudogout). Septic arthritis is an emergency, and delaying arthrocentesis or antibiotics can permanently damage a joint.
Diagnosing osteoarthritis
In a patient with a typical clinical pattern, OA may be diagnosed from history and examination without routine extensive laboratory or imaging tests. Plain radiography can show joint-space narrowing, osteophytes, subchondral sclerosis and cystic changes when imaging is needed. In a typical uncomplicated case, MRI is rarely a necessary first test [1].
Blood tests can help evaluate alternative or coexisting inflammatory disease when indicated, but an elevated CRP does not establish RA and a normal CRP does not prove OA. Consider injury, bursitis, tendon disease, gout and other explanations.
Diagnosing rheumatoid arthritis
RA diagnosis rests on clinical synovitis, joint pattern, symptom duration and supportive evidence. Useful tests may include rheumatoid factor (RF), anti-cyclic citrullinated peptide antibodies (anti-CCP/ACPA), ESR and CRP, along with imaging of affected joints [2–4].
Seronegative RA exists, so negative RF and anti-CCP do not exclude disease. Conversely, RF can be positive in other conditions or some healthy individuals. Early referral to rheumatology is important when persistent small-joint swelling or inflammatory arthritis is suspected, even before classic erosions appear.
2026 ACR osteoarthritis update: what changed?
The 14 September 2026 ACR update reinforces foundational treatment with exercise, self-management, appropriate weight loss, topical and oral NSAIDs when suitable, and selected intra-articular glucocorticoid injections [1]. It stresses patient preference, comorbidities, access and combining non-drug and pharmacological approaches.
Two notable conditional recommendations are new:
- GLP-1 receptor agonists may be considered in eligible people with knee OA to help achieve optimal weight when clinically appropriate. This does not mean GLP-1 drugs are universally recommended for all arthritis, or that they directly regenerate cartilage.
- Methotrexate may be considered for selected people with erosive hand osteoarthritis. This is a narrow conditional recommendation and must not be confused with routine methotrexate treatment of standard knee or hip OA [1].
Conditional means suitability is uncertain or situation-dependent and requires informed clinical discussion. The update does not make injectable biologics or systemic immunosuppressants routine therapy for every person with OA.
First-line osteoarthritis management: movement and function
Exercise is among the strongest OA interventions. Structured strengthening, aerobic conditioning, flexibility and balance work can reduce pain and improve function. Physical therapy helps tailor activities to the joint, gait limitations and coexisting conditions. Gradual activity increases are appropriate; pain flares may require temporary modifications rather than total inactivity [1].
For people with excess weight and symptomatic knee or hip OA, weight reduction can reduce mechanical load and improve symptoms. The plan should avoid stigma and emphasize sustainable nutrition, strength and mobility rather than a rigid number on a scale.
Osteoarthritis medicines: topical NSAIDs, oral NSAIDs and injections
| Intervention | When it may help | Precautions |
|---|---|---|
| Topical NSAIDs, e.g. diclofenac | Often useful for knee or hand OA when the affected joint is superficial. | Skin reactions; systemic exposure is lower but not zero. |
| Oral NSAIDs, e.g. ibuprofen, naproxen | Short-term reduction of OA pain when appropriate. | GI bleeding, kidney injury, blood-pressure and cardiovascular risks; use lowest effective exposure. |
| Intra-articular corticosteroid injection | Short-term symptom relief in selected knee/hip or other joints. | Not a structural cure; assess infection, diabetes and repeat-injection risks. |
| Duloxetine | Conditional option for selected chronic OA pain presentations. | Nausea, interactions, blood-pressure changes and withdrawal risks. |
| Paracetamol/acetaminophen | Sometimes suitable when alternatives are contraindicated. | Limited average efficacy in OA; avoid excessive dose and liver toxicity. |
Long-term strong opioids are generally not a preferred OA treatment because harms can outweigh sustained benefit. Topical options, physical rehabilitation, assistive devices and proper assessment should be considered before escalating potentially dangerous medicines [1].
Are joint supplements and hyaluronic acid effective?
Glucosamine, chondroitin, collagen and other supplements have inconsistent or condition-specific evidence and may not meaningfully reduce symptoms for most patients. Their quality and drug interactions vary. Intra-articular hyaluronic acid is not routinely recommended by several major guidelines for knee/hip OA because average benefit is limited relative to cost and procedural burden [1].
No supplement has been shown to reliably rebuild damaged cartilage or replace exercise and appropriate pain management. A clinician should distinguish evidence-supported interventions from commercial promises.
When does OA need joint-replacement evaluation?
Hip or knee arthroplasty may help when pain and functional limitation remain substantial despite suitable nonoperative management and imaging supports advanced OA. Referral decisions depend on personal goals, comorbidities, severity and expected benefit, not only age or the appearance of an X-ray.
Priorities include realistic expectations, rehabilitation readiness and shared decisions about surgical risk. Infection, severe unexplained pain or rapidly progressive disease may require a different specialist assessment first.
RA: DMARDs are the central treatment
NSAIDs and corticosteroids may reduce RA pain or swelling temporarily but do not replace DMARDs that alter long-term inflammatory disease activity. The EULAR 2025 treatment update, published in 2026, recommends starting a DMARD promptly after RA diagnosis with a treat-to-target strategy aiming for sustained remission or low disease activity [2,3].
Methotrexate (MTX) should be part of the first treatment strategy in most appropriate patients, often with short-term glucocorticoids that are tapered as quickly as clinically feasible. Leflunomide or sulfasalazine are alternatives when methotrexate is contraindicated or poorly tolerated [2].
How methotrexate works and how it is monitored
At low weekly anti-inflammatory doses, methotrexate alters folate-related pathways and increases anti-inflammatory signaling, including adenosine-mediated effects. It is a standard conventional synthetic DMARD (csDMARD) for RA. It is usually prescribed once weekly, not daily; taking a weekly RA dose daily can cause fatal toxicity [2].
Monitoring includes full blood count, kidney and liver function and assessing mouth ulcers, infection symptoms and adverse effects. Folic acid supplementation is commonly used to improve tolerability. Methotrexate has important pregnancy-related risks and should be managed with specialist reproductive counseling.
RA treat-to-target: reassessment and escalation
The EULAR 2025 update recommends monitoring active RA every 1–3 months. If there is no improvement by roughly three months or the treatment target is not reached by six months, the regimen should be adjusted. With inadequate csDMARD response, a biologic DMARD is generally added; selected JAK inhibitors can also be considered after evaluating major safety risks [2,3].
| RA medicine category | Examples | Important issues |
|---|---|---|
| csDMARDs | Methotrexate, leflunomide, sulfasalazine. | Laboratory monitoring, organ toxicity and reproductive counseling. |
| TNF inhibitors | Adalimumab, etanercept, infliximab and others. | Infection risk; TB and hepatitis screening before selected biologics. |
| Other biologic DMARDs | Abatacept, rituximab, tocilizumab, sarilumab. | Agent-specific infection, infusion/injection and monitoring risks. |
| JAK inhibitors | Tofacitinib, baricitinib, upadacitinib and others. | Risk review for serious infections, venous thrombosis, malignancy and major cardiovascular events. |
Selection depends on prior treatment, disease activity, infection risk, vaccination, cost, reproductive plans and comorbidities. Do not assume all biologics or JAK inhibitors have equivalent safety and dosing.
Biologics and JAK inhibitors: safety before treatment
Before certain RA immunosuppressive therapies, clinicians screen for tuberculosis and hepatitis B, review vaccinations, blood counts and organ function, and assess infection or malignancy history. JAK inhibitors may be effective but carry specific warnings about major cardiovascular events, cancer, thrombosis and serious infections; EULAR recommends individualized risk appraisal [2].
In sustained remission, some RA therapy can sometimes be carefully tapered, but stopping all DMARDs may trigger relapse. Patients should not discontinue therapy simply because joints feel better for a few weeks.
RA extra-articular disease and cardiovascular risk
RA can be associated with interstitial lung disease, scleritis, nodules, anemia and increased cardiovascular risk. New breathlessness, eye pain or rapidly progressive symptoms require appropriate assessment and may change medicine choices. Smoking cessation, vaccination, blood-pressure and lipid management complement inflammatory disease control [2].
Persistent high inflammatory burden may increase risk even when standard cardiovascular risk calculators appear reassuring. A coordinated care plan should consider the whole patient rather than joint symptoms alone.
Can someone have both OA and RA?
Yes. People with longstanding RA can also develop OA, especially with aging or prior joint injury. A new mechanical knee pain episode in someone whose RA is well-controlled may not represent inflammatory flare, while persistent warm swelling and prolonged stiffness suggest active synovitis. Increasing immunosuppressants without assessing the source of pain can cause avoidable harm.
Ultrasound or imaging may help in uncertain cases; evaluation can also consider fibromyalgia, tendon disorders and neuropathic pain. Treatment should target each condition appropriately.
Urgent symptoms to recognize
A hot, acutely swollen joint with fever or severe pain may indicate septic arthritis and needs emergency assessment, particularly in a person using immunosuppressants or with a prosthetic joint. Sudden severe eye pain or visual loss can reflect ocular inflammatory complications. A patient with RA taking immunosuppressants should report serious infection symptoms promptly.
Frequently asked questions
Is osteoarthritis simply old age?
No. It is a whole-joint disease influenced by injury, loading, genetics and age; younger people can develop OA.
Do normal RF and anti-CCP exclude rheumatoid arthritis?
No. Seronegative RA exists, so persistent inflammatory synovitis deserves evaluation.
Are NSAIDs enough to prevent RA joint destruction?
No. Early DMARD therapy is needed to control inflammatory disease and reduce damage [2].
Did the 2026 ACR guideline approve methotrexate for all OA?
No. It introduced a conditional option only for selected erosive hand OA, not routine knee or hip OA [1].
Can GLP-1 medicines treat every type of arthritis?
No. The new conditional recommendation relates to appropriate weight management for selected people with knee OA [1].
How often should active RA be reassessed?
Typically every one to three months, adjusting the treatment if improvement or targets are not achieved on schedule [2].
Key takeaways
OA and RA are not interchangeable diagnoses. OA care emphasizes exercise, self-management and safe symptom treatment, with narrow new conditional options in the 2026 ACR update. RA requires early DMARD therapy, usually methotrexate, and treat-to-target follow-up, with escalation and JAK safety review according to 2025 EULAR recommendations published in 2026. Hot swollen joints with systemic illness require emergency evaluation.
References
- American College of Rheumatology. ACR updates osteoarthritis guidance, reinforcing personalized, comprehensive care. 14 Sep 2026.
- Smolen JS, Edwards CJ, et al. EULAR recommendations for management of rheumatoid arthritis with synthetic and biological DMARDs: 2025 update. Ann Rheum Dis. 2026;85:991–1009. doi:10.1016/j.ard.2026.01.023.
- American College of Rheumatology. Rheumatoid arthritis: patient and clinical information. Accessed 9 Nov 2026.
- American College of Rheumatology. Osteoarthritis: symptoms and management. Accessed 9 Nov 2026.
- National Institute for Health and Care Excellence. Osteoarthritis in over 16s: diagnosis and management (NG226). NICE.
Medical disclaimer: Educational information only. Arthritis diagnosis, RA DMARD treatment and osteoarthritis drug or injection choices require individualized professional care. Methotrexate is often a weekly medicine with serious risks if taken daily. A hot swollen joint with fever may be septic arthritis and needs emergency assessment.
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.